Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know
Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.
Moderna's stock skyrocketed by over 120% following the announcement of a successful Phase 3 trial for their personalized cancer vaccine. Merck's stock also experienced a significant jump of more than 10%. The trial involved more than 1,100 patients with higher-risk melanoma, a severe form of skin cancer. The experimental vaccine, combined with Merck's drug Keytruda, showed promising results, significantly increasing the time patients lived without their melanoma returning.
Moderna CEO Stephane Bancel called the results a major moment for medicine and patients. The companies plan to present the full data at an upcoming international medical meeting and are expected to begin discussions with regulatory agencies about the treatment's safety and approval within the next few months.
Written by urgent.news from Hindustan Times - World News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
